Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus

Biochemical and Biophysical Research Communications

Volumn 385, Issue 3, 2009, Pages 390-394

  Rungrotmongkol, Thanyada ^a   Intharathep, Pathumwadee ^a   Malaisree, Maturos ^a   Nunthaboot, Nadtanet ^b   Kaiyawet, Nopphorn ^a   Sompornpisut, Pornthep ^a   Payungporn, Sanchai ^a   Poovorawan, Yong ^a   Hannongbua, Supot ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

2009 H1N1 influenza A virus; Amantadine; M2 channel; Molecular dynamics simulations; Neuraminidase; Oseltamivir; Rimantadine

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; SIALIDASE;

2009 H1N1 INFLUENZA; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG SENSITIVITY; EPIDEMIC; EVOLUTIONARY HOMOLOGY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIMULATION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADAMANTANE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS;

EID: 67349211850     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.066     Document Type: Article

References (23)

1. WHO, Epidemic and Pandemic Alert and Response (EPR). Available from: , (accessed May 2009).
2. Emedicine. Available from:
3. WHO, Media centre. Influenza A(H1N1). Available from: , (accessed May 2009).
4. De Clercq E. Antiviral agents active against influenza A virus. Nat. Rev. Drug Discov. 5 (2006) 1015-1025
5. CDC, Antiviral Drugs and H1N1 Flu (Swine Flu). Available from: , (accessed May 2009).
6. Aruksakunwong O., Malaisree M., Decha P., Sompornpisut P., Parasuk V., Pianwanit S., and Hannongbua S. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. Biophys. J. 92 (2007) 798-807
7. Malaisree M., Rungrotmongkol T., Decha P., Intharathep P., Aruksakunwong O., and Hannongbua S. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 71 (2008) 1908-1918
8. M. Malaisree, T. Rungrotmongkol, N. Nunthaboot, O. Aruksakunwong, P. Intharathep, P. Decha, P. Sompornpisut, S. Hannongbua, Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation, Amino Acids (2009), doi:10.1007/s00726-008-0201-z.
9. Intharathep P., Laohpongspaisan C., Rungrotmongkol T., Loisruangsin A., Malaisree M., Decha P., Aruksakunwong O., Chuenpennit K., Kaiyawet N., Sompornpisut P., Pianwanit S., and Hannongbua S. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J. Mol. Graph. Model. 27 (2008) 342-348
10. Laohpongspaisan C., Rungrotmongkol T., Intharathep P., Malaisree M., Decha P., Aruksakunwong O., Sompornpisut P., and Hannongbua S. Why amantadine loses its function in influenza M2 mutants: MD simulations. J. Chem. Inf. Model. 49 (2009) 847-852
11. Russell R.J., Haire L.F., Stevens D., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
12. Hu J., Asbury T., Achuthan S., Li C., Bertram R., Quine J.R., Fu R., and Cross T.A. Backbone structure of the amantadine-blocked trans-membrane domain M2 proton channel from influenza A virus. Biophys. J. 92 (2007) 4335-4343
13. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19 (1998) 1639-1662
14. T. Rungrotmongkol, T. Udommaneethanakit, M. Malaisree, N. Nunthaboot, P. Intharathep, P. Sompornpisut, S. Hannongbua, How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? (2009), Submitted for publication.
15. Wall I.D., Leach A.R., Salt D.W., Ford M.G., and Essex J.W. Binding constants of neuraminidase inhibitors: an investigation of the linear interaction energy method. J. Med. Chem. 42 (1999) 5142-5152
16. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., and Gamblin S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453 (2008) 1258-1261
17. Abed Y., Nehmé B., Baz M., and Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2. Antiviral Res. 77 (2008) 163-166
18. Boivin G., and Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54 (2002) 143-147
19. Mishin V.P., Hayden F.G., and Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 (2005) 4515-4520
20. Tang J.W., Ngai K.L.K., Wong J.C.L., Lam W.Y., and Chan P.K.S. Emergence of adamantane-resistant influenza A (H3N2) viruses in Hong Kong between 1997 and 2006. J. Med. Virol. 80 (2008) 895-901
21. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 (2006) 891-894
22. Simonsen L., Viboud C., Grenfell B.T., Dushoff J., Jennings L., Smit M., Macken C., Hata M., Gog J., Miller M.A., and Holmes E.C. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24 (2007) 1811-1820
23. Pielak R.M., Schnell J.R., and Chou J.J. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. USA 106 (2009) 7379-7844